BiotechTube

PLX3397 + Pembrolizumab

Phase 1/2Terminated
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma

Conditions

Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer

Trial Timeline

Jul 2, 2015 → Oct 12, 2018

NCT ID
NCT02452424

About PLX3397 + Pembrolizumab

PLX3397 + Pembrolizumab is a phase 1/2 stage product being developed by Daiichi Sankyo for Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02452424. Target conditions include Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02452424Phase 1/2Terminated

Competing Products

20 competing products in Melanoma

See all competitors
ProductCompanyStageHype Score
Binimetinib Oral TabletBiotrialPhase 1
25
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
77
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
FYB206 + KeytrudaFormycon AGPhase 1
25
PLX3397Daiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
DS-8273a + NivolumabDaiichi SankyoPhase 1
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
33
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
YM155Astellas PharmaPhase 2
52
YM155 + DocetaxelAstellas PharmaPhase 2
52
Denileukin diftitoxEisaiPhase 2
52
E7080EisaiPhase 1
33
lenvatinib + pembrolizumabEisaiPhase 2
52
MORAb-004 (monoclonal antibody)EisaiPhase 2
52
Pembrolizumab + LenvatinibEisaiPhase 2
52
Lenvatinib + Lenvatinib + DacarbazineEisaiPhase 1/2
41
E7386 + Pembrolizumab + LenvatinibEisaiPhase 1/2
41

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85